ClinicalTrials.gg
Not yet recruitingNCT07316712Updated Jan 5, 2026

Effect of TECAR (Transfer of Energy Capacitive and Resistive) Therapy on Chronic Supraspinatus Tendinitis

An interventional study of Conventional treatment and TECAR (Transfer of Energy Capacitive and Resistive) Therapy in Supraspinatus Tendinitis, sponsored by Cairo University. Not yet recruiting at 1 site in Egypt. Open to participants aged 30 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-01-05.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
30 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Tendinopathy by Cairo University — 4 open to participants now, 4 under way, none of them phase 3. Tendinopathy · Cairo University.

Planned enrollment
7th of 10
46 · median 50
Started
2025
with 1 other
No phase
10 of 10
4 open now
Registered
7th of 10
by date

Among the 10 studies in Tendinopathy by Cairo University, this one is the 7th largest by planned enrollment, is one of 2 that started in 2025, is one of 10 with no phase, and was the 7th registered.

Tendinopathy

399 studies on the registry are indexed under Tendinopathy; 77 are open to participants now.

Browse Tendinopathy studies →

Open to participants now

4 of the 10 studies in Tendinopathy by Cairo University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 46 Tendinopathy studies recruiting now, 17 (37%) set no upper age limit and 22 (48%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 30 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Tendinopathy by Cairo University, or all of them as a file.
02

Study summary

This study aims to investigate the effect of TECAR therapy on pain, shoulder range of motion, functional disability, and handgrip strength in patients with grade II supraspinatus tendinitis.

Read the detailed description

Tendinopathy occurs when pain arises in a tendon near its origin or insertion due to repetitive activities and reduced functional levels. It happens when the tendon does not properly heal. Thirty percent of tendinopathies related to musculoskeletal conditions are associated with shoulder pain, and supraspinatus tendinitis is the third most prevalent problem.

The supraspinatus tendon, part of the rotator cuff of the shoulder joint, is particularly affected. Aging is also a common factor leading to supraspinatus tendon injuries. The primary function of the supraspinatus muscle is shoulder abduction, particularly during movements that elevate the arm overhead. During these motions, the supraspinatus tendon repeatedly passes beneath the acromion process of the scapula, which can result in impingement and subsequent inflammation. An unexpected force or trauma may cause a partial or complete tendon rupture if this condition progresses.

Transfer of Energy Capacitive and Resistive (TECAR) offers a unique variety of treatments for chronic and acute pathologies, with contraindications such as pregnancy, pacemakers, and sensitivity to high temperatures. It should be noted that this new technology is a valuable tool in treating various pathologies, particularly when compared with other therapies in terms of the presence and/or absence of specific positive effects. TECAR also has distinct characteristics that are effective even when other treatments fail. This therapy balances the therapist's manual skills and the specialized energy that this technology offers, resulting in increasingly satisfactory outcomes for therapists and patients.

03

Conditions studied

  • Supraspinatus Tendinitis

Browse trials for

04

Who can participate

Ages eligible
30 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Supraspinatus Tendinitis grade II based on Neer's classification, confirmed by special tests, signs, and symptoms of grade I and II Supraspinatus Tendinitis for the past month, and taking non-steroidal anti-inflammatory drugs as suggested by the physician.
  • All patients will have a between 18.5 and 29.9 kg/m².

Exclusion criteria

Exclusion Criteria:

  • Other grades of Supraspinatus Tendinitis.
  • Any past shoulder surgical interventions.
  • Instability of the shoulder joint due to other reasons, Acromioclavicular Joint Arthritis.
  • Non-cooperative subjects.
  • Diabetes
  • Pregnant or lactating women.
  • Serious neuromuscular or cardiovascular diseases.
  • Systemic illness and severe COVID-19 cases will be excluded from this study.
  • Pacemakers
  • Heat Sensitivity
  • Metal Implants
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    Conventional treatment + TECAR therapy

    The experimental group will receive conventional physiotherapy sessions as the active comparator group, in addition to TECAR therapy at the end of each session. Sessions will be received for three weeks (nine sessions, three times per week).

    Other: Conventional treatment · Device: TECAR (Transfer of Energy Capacitive and Resistive) Therapy

  • Active comparator
    Conventional treatment

    The active comparator group will receive conventional physiotherapy sessions for three weeks (nine sessions, three times per week).

    Other: Conventional treatment

Interventions

  • OtherConventional treatment

    All patients in both groups will receive conventional treatment, 3 sessions per week for 3 weeks. The conventional methods for treating supraspinatus tendinitis include shoulder swings, painless range of motion (ROM) exercises, shoulder joint active-assisted exercises, resistance exercises to improve muscle strength, and pain-reducing physiotherapy modalities like ultrasound.

  • DeviceTECAR (Transfer of Energy Capacitive and Resistive) Therapy

    Patients in the experimental group only will receive TECAR therapy, 3 sessions per week for 3 weeks. The treatment will start with an automatic capacitive energy transfer for 10 minutes. Next, the capacitive plaque will be replaced by the resistive electrode, and the neutral electrode will be fixed

06

What researchers measure

Primary outcomes

  1. Assessment of Pain Intensity of Shoulder Joint by Numerical Rating Scale (NRS)

    The Numerical Rating Scale (NRS) will evaluate shoulder pain when using the NRS. Patients will be asked to rate their pain on a scale from 0 to 10, where 0 represents "no pain" and 10 represents "the worst pain possible.

    Time frame: 3 weeks

Secondary outcomes

  1. Assessment of Shoulder abduction range of motion

    A digital goniometer will be used to assess shoulder joint abduction range of motion in patients with chronic supraspinatus tendinitis before and after the treatment sessions. Measurements will be taken with the patient in the supine position. The fulcrum of the goniometer will be centered at the anterior aspect of the acromion process, the stationary arm will be aligned parallel to the midline of the torso, and the moving arm will be aligned with the midline of the humerus, pointing toward the medial epicondyle of the elbow.

    Time frame: 3 weeks

  2. Assessment of Shoulder External Rotation range of motion

    Shoulder joint external rotation range of motion will also be assessed using a digital goniometer before and after the treatment sessions in patients with chronic supraspinatus tendinitis. The patient will be positioned supine during measurement. The fulcrum of the goniometer will be centered over the olecranon process of the elbow, the stationary arm will be aligned perpendicular to the floor, and the moving arm will be aligned with the ulna, pointing toward the ulnar styloid process.

    Time frame: 3 weeks

  3. Assessment of Handgrip strength by handheld dynamometer

    A JAMAR hand dynamometer (Sammons Preston Inc, Bolingbrook, IL, USA) will be used to measure grip strength in kilograms. The Jamar is small and portable but relatively heavy at 1.5 lb. The dial reads force in both kilograms and pounds, with markings at intervals of 2 kg or 5 lb, allowing assessment to the nearest 1 kg or 2.5 lb. The reading error is reported to be greater at lower loadings. This method has high test-retest reliability. Also, it has both inter and intra-rater reliability.

    Time frame: 3 weeks

  4. Assessment of Functional disability by QuickDASH Scale (Arabic Version)

    The QuickDASH includes 30 items, with six items about symptoms (3 about pain, 1 for tingling/numbness, 1 for weakness, 1 for stiffness) and 24 about function (21 about physical function, 3 about social/role function). For each question, the subject rated the performance in the last week on a 5-point scale (1 = no difficulty to perform or no impact; 5 = unable to do or high impact). The raw score is the sum of all answers (maximum score: 150; minimum score: 30). The raw score is transformed into a zero to 100 scale (= total DASH). Zero is no disability and 100 maximum disability.

    Time frame: 3 weeks

07

Study locations

1 site
  • CAN Center outpatient clinic
    Cairo, Egypt
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Feb 2026, 1 month later.

Of 174 non-industry interventional studies with no phase under Tendinopathy, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 38. This study's planned 1 month is below that.

Counting every sponsor, half of 183 studies reached it within 20 months; a quarter within 7 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2025
First posted
Jan 5, 2026
StartEst.
Dec 30, 2025
Primary completionEst.
Feb 15, 2026
CompletionEst.
Feb 28, 2026
Last update
Jan 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07316712
Lead sponsor
Cairo University
Responsible party
Mohamed Gamal Ibrahem Alghamry (Principal Investigator, Cairo University) — Principal investigator
First posted
Jan 5, 2026
Start date
Dec 30, 2025 (estimated)
Primary completion
Feb 15, 2026 (estimated)
Completion
Feb 28, 2026 (estimated)
Last update
Jan 5, 2026

Study contacts

Mohamed Gamal Ibrahem Alghamry, B.Sc
Contact
Mohamed.gamal.2651997@gmail.com
+20 114 448 1731
Hend Hamdy Mohamed Ahmed, PhD
Contact
Hanaa Kenawy Atta, PhD
study chair · Assistant Professor, Cairo University
Hend Hamdy Mohamed Ahmed, PhD
study director · Lecturer, Cairo university

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion